Chapel Hill, NC, United States of America

Jeffery Edmond Cobb

USPTO Granted Patents = 7 

 

 

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Jeffery Edmond Cobb: Innovative Mind from Chapel Hill, NC

Introduction

Jeffery Edmond Cobb is an accomplished inventor based in Chapel Hill, NC, with a remarkable portfolio of five patents to his name. His contributions to the field of biochemistry and therapeutics showcase his commitment to developing novel solutions for health-related challenges.

Latest Patents

Among his latest inventions is a patent for "Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy." This groundbreaking work focuses on creating novel imidodicarbonimidic diamides, particularly N-[2-(indol-3-yl)alkylene]-linked and N-[2-(pyrrolopyridin-3-yl)alkylene]-linked compounds. These innovative compounds are believed to act as organic cation transporter selective agents, potentially useful in treating diseases linked to reduced activity of the 5' adenosine monophosphate-activated protein kinase (AMPK).

Career Highlights

Throughout his career, Jeffery has collaborated with several prominent companies in the biotechnology space, including Metabolon, Inc., and Novatarg, Inc. His tenure at these organizations has allowed him to engage in cutting-edge research and development efforts.

Collaborations

In his professional journey, Jeffery has worked alongside notable colleagues such as Kenneth Batchelor and Kristjan S. Gudmundsson. This collaboration has facilitated the exchange of ideas and accelerated innovation within their respective fields.

Conclusion

Jeffery Edmond Cobb continues to make significant strides in the world of medical chemistry through his inventive contributions. With his ongoing research and innovative spirit, he remains an influential figure in the development of therapies targeting critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…